MicroRNA 4772 (miR-4772)

MicroRNA 4772 (miR-4772, also known as hsa-mir-4772 or MIR4772) is a small non-coding RNA molecule that plays a role in the post-transcriptional regulation of gene expression. It functions by binding to mRNA targets and promoting either mRNA degradation or inhibition of translation, thereby modulating the expression levels of genes involved in cancer, immune regulation, and cellular differentiation. miR-4772-3p, a processed form of this molecule, has been described as a potential oncogenic or prognostic marker in several cancers (glioblastoma, colon, breast, ovarian, pancreatic), as well as a biomarker for sepsis and Alzheimer’s disease. Its altered expression in blood or tissue samples is associated with disease diagnosis, progression, prognosis, and possibly response to immunotherapy. Target genes of miR-4772 include RTN4 (NOGO) and RAB9A, which are implicated in cancer cell adhesion, migration, and the Ras oncogene family. Its therapeutic targeting is investigational, with no approved drugs available as of this review.

Other names

hsa-mir-4772miR-4772MIR4772hsa-miR-4772

As a microRNA, miR-4772 regulates target gene expression by binding to complementary sequences in the 3’ untranslated region (UTR) of mRNAs, leading to transcript degradation or inhibition of translation. Downregulation of miR-4772-3p is associated with impact on genes like RTN4 (NOGO) and RAB9A, which play roles in cellular processes relevant to cancer. May indirectly contribute to cancer or disease processes through regulation of signaling pathways such as MAPK and PI3K-Akt.